How do Avita Medical (ASX:AVH) shares stack up against Polynovo and Aroa Biosurgery?

Avita (ASX:AVH) shares have been sliding lower. With the release of its quarterly results, how does Avita stack up against its competitors?

| More on:
medical asx share price represented by three doctors in a row

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ASX mid-cap healthcare company Avita Medical Inc (ASX: AVH) released its second-quarter FY21 results to the market last week. Despite recording positive revenue numbers, the Avita share price has continued to slide lower over the last five days. At their current price of $6.40, Avita shares are now more than 30% below their 52-week high price of $9.58.

What does Avita do?

Avita is one of a number of biotech companies currently trading on the ASX specialising in skin tissue repair, particularly relating to serious burns or other traumatic injuries. Its competitors in this space include Polynovo Ltd (ASX: PNV) and New Zealand-based Aroa Biosurgery Ltd (ASX: ARX).

Avita's flagship technology, its RECELL System, uses a sample of the patient's own skin to create "spray-on skin cells" which can then be applied to wounds or other affected areas on the patient's body. The company claims its technology harnesses the skin's own regenerative properties to help heal severe wounds.

What was in the company's results?

Avita reported a 57% year-on-year jump in revenues to $5.1 million for the December quarter. However, it's worth noting that this result was actually flat against the previous quarter, ended 30 September 2020. Procedural volumes for the December quarter were also slightly lower than the prior quarter.

The company's inability to provide any firm earnings guidance for the remainder of FY21 may have also scared away some investors, driving the Avita share price lower. Avita revealed that nearly half of its revenues came from just 20 accounts, all of which are exposed to the effects of COVID-19.

How does Avita stack up against its competitors?

Avita's December quarter results were actually surprisingly similar to those of Aroa Biosurgery. Aroa, whose flagship product is a biodegradable tissue repair device originally derived from a sheep's forestomach, reported revenues of NZ$5.9 million for the December quarter.

This is also similar to Polynovo. In a first-half trading update released to the market in January, Polynovo stated that sales revenues were up 31% versus the first half of FY20, despite slow months in November and December. This would imply first-half sales of a little over $11 million (1H FY20 sales revenue was $8.57 million), or about $5.5 million on an average quarterly basis. Again, this puts it roughly in line with both Aroa and Avita.

All three companies are also trying to expand their global footprint. Avita recently redomiciled to the United States, as this is where it generates the overwhelming majority of its revenues ($5 million of its $5.1 million December quarter revenues came from the US market).

Polynovo has been expanding rapidly into new European markets, most recently Poland and Turkey, and already has a presence in the US and Taiwan. And Aroa has recently received regulatory approvals to start distributing its products in India.

At the moment, it's difficult to tell which of these companies will end up on top. The next 12 months may be a crucial period for Avita, Polynovo and Aroa. It will be interesting to see whether all three companies can deliver on their competing growth strategies.

Rhys Brock owns shares of Avita Medical Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Avita Medical Limited and POLYNOVO FPO. The Motley Fool Australia has recommended Avita Medical Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »